Table 1 Retrospective analysis 1: Results for practices that had implemented the extended-release moxidectin injectable ProHeart® 6 (PH6) and/or ProHeart® 12 (PH12) in their pharmacy stock
Product | Time period covered by doses dispensed annually | Corresponding monthly doses per year | Number of dogs | Proportion (%) | Monthly doses per dog dispensed annually |
|---|---|---|---|---|---|
MHWP | 1–3 months | 2 | 338,067 | 23.6 | |
4–5 months | 4.5 | 57,150 | 4.0 | ||
6 months | 6 | 423,880 | 29.6 | ||
7–9 months | 8 | 91,655 | 6.4 | ||
10–11 months | 10.5 | 30,433 | 2.1 | ||
12+ months | 12 | 488,847 | 34.2 | ||
SUM | 1,430,032 | 100.0 | 7.3 | ||
PH6 | 6 months | 6 | 202,864 | 64 | |
12 months | 12 | 111,823 | 36 | ||
SUM | 314,687 | 100 | 8.1 | ||
PH12 | 12 months | 12 | 324,001 | 100 | 12.0 |